Xilio Therapeutics, Inc.
XLO
$-0.03
Change (1 day)
$1.93
Year High
$0.49
Year Low
Categories
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Therapeutics, Inc. (XLO) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -33,247,000 | 24.1 M | 60.93 M | 48.13 M | |
| 2022 | -100,446,000 | 33.52 M | 139.17 M | 124.5 M | |
| 2021 | -177,517,000 | 32.63 M | 218.06 M | 202.52 M | |
| 2020 | 1.98 M | 119.6 M | 36.32 M | 20.59 M | |
| 2019 | -30,214,000 | 92.25 M | 62.72 M | 51.1 M |